Hepatocellular carcinoma (HCC) patients with an active HGF/MET signaling pathway have a significantly worse prognosis. Moreover, MET activation triggered by anti-angiogenic therapies, such as sunitinib and sorafenib, can contribute to metastasis. In the current study, we first verified an association of phosphorylated MET (p-MET) with resistance to sorafenib as postoperative adjuvant therapy in a set of human HCC samples. In the next set of experiments, we examined anti-tumor effects of cabozantinib, a dual inhibitor of MET and VEGFR2, using cultured HCC cells, mouse xenograft and metastatic models. Both the in vitro and in vivo results showed that cabozantinib could inhibit HCC cells growth and metastasis. Based on an understanding of the drug's mechanism and its effectiveness in multiple HCC cells and in vivo models, we believe that cabozantinib should be a promising strategy for the treatment of HCC in the future clinical practice. 
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related death worldwide (1) . Despite improvements in diagnostic and therapeutic strategies, the prognosis of HCC still remains poor (2) (3) (4) . Inhibiting angiogenesis has been used as a strategy in the treatment of HCC (5, 6) . For example, sorafenib, a vascular endothelial growth factor receptor (VEGFR) inhibitor with activity against platelet derived growth factor receptor (PDGFR), c-Kit receptor, RAF and p38 signal transduction pathways, has become a standard treatment in patients with advanced HCC (7) . Even though sorafenib improves the median survival in advanced HCC, the median overall survival remains less than one year partly due to that many patients eventually become resistant to this drug (8, 9) . In addition, sorafenib, like other VEGFR inhibitors such as sunitinib and cediranib, possesses the possibility to increase the invasiveness and/or metastatic potential of tumors (10) (11) (12) . Thus, developing inhibitors that simultaneously inhibit VEGF and other pathways involved in tumor invasion and metastasis may confer broad and potent anti-tumor efficacy.
and metastasis (10, 11, 19) . Therefore, blockade of both MET and VEGFR pathways may achieve better treatment outcome in HCC.
Tivantinib was initially reported as a MET selective inhibitor and demonstrated a nearly doubling of progression-free survival (PFS) and overall survival (OS) in HCC patients with high expression of MET (20) . However, subsequent studies confirmed that tivantinib is not a MET inhibitor but an antimitotic agent that kills tumor cells independently of MET (21, 22) . Cabozantinib is an oral small-molecule tyrosine kinase inhibitor that blocks phosphorylation of MET and VEGFR2 and also has activity against AXL, RET, and KIT (23) . Results from phase II and III clinical trials demonstrated that cabozantinib exhibited encouraging clinical activity in multiple human cancers including castration-resistant prostate cancer, medullary thyroid cancer, and HCC with manageable side effects (24) (25) (26) . Although cabozantinib has clinical benefit, the anti-tumor mechanism of cabozantinib in HCC has not been fully elucidated. Furthermore, anti-tumor agents that administered to patients before knowing their mechanism of action may be misleading in the development of predictive biomarkers. In the present study, we investigated whether cabozantinib could inhibit tumor growth and metastasis, and explored the molecular mechanism of anti-tumor activity of cabozantinib in HCC.
January 2008 and December 2012. These patients were pathologically diagnosed as HCC with microvascular invasion. Since microvascular invasion is one of the most powerful factors associated with the recurrence of HCC after resection (27) , patients consented to take sorafenib as the adjuvant therapy. The criteria for following-up, definition of sorafenib resistance and high expression of MET were described in the Supplementary Materials and Methods. The characteristics of all patients were summarized in Supplementary Table S1 .
Cell lines and culture conditions
SK-HEP1 and HepG2 cells were obtained from the American Type Culture Collection (ATCC).
MHCC97L and MHCC97H cells were supplied by the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). These cell lines were maintained in DMEM (GIBCO BRL, Grand Island, NY, USA) supplemented with 10% FBS (fetal bovine serum; GIBCO BRL, Grand Island, NY, USA), 100 U/ml penicillin, and 100 U/ml streptomycin. HUVECs (human umbilical vein endothelial cells) were purchased from ScienCell Research Laboratories (San Diego, CA) and were maintained in EBM-2 medium (Cambrex Bioscience, MD, USA) according to the manufacturer's instructions. The four HCC cell lines were authenticated using short tandem repeat (STR) DNA testing by Beijing
Animal experiments

Animal care
Female BALB/c athymic nude mice, 5 to 6 weeks old (Experimental Animal Center of Sun Yat-sen University, China), were used for in vivo studies. All animals were fed a standard diet ad libitum and housed in a temperature-controlled animal facility with a 12/12 h light/dark cycle. All procedures were performed according to the National Institutes of Health Guide for Care and Use of Laboratory Animals and were approved by the Bioethics Committee of Sun Yat-sen University. 
Tumor implantation and growth
MHCC97H and
Immunohistochemical analysis
Frozen, 5 μm thick sections of tumor samples were prepared to determine vessel density with an anti-CD31 (1:100) antibody. To evaluate proliferation and apoptosis, 5 μm paraffin-embedded sections were stained with anti-Ki67 (1:50) and anti-cleaved PARP (1:50) antibodies, respectively.
After blocking endogenous peroxidase activity, the sections were incubated overnight with the primary antibodies at 4°C. Detection was completed with the Polink-2 Plus IHC Detection System (Beijing Zhongshan Biotechnology Co., Beijing, China) according to the manufacturer's instructions. 
Statistical analysis
Statistical analyses were performed with mean ± standard deviation (SD) values using Student's t-test and two-way analysis of variance (ANOVA) with the Bonferroni's correction. Statistical significance was concluded at P < 0.05.
Results
The expression of p-MET in resected HCC specimens is associated with resistance to adjuvant sorafenib therapy
The expression of MET in HCC specimens were detected by immunostaining. We observed that MET is overexpressed in most of tumor tissues (data not shown), whereas p-MET is highly expressed in approximately 27.6% HCC patients. Notably, we found that positive p-MET staining was associated with the therapeutic response to sorafenib. Specifically, seven of 12 (58.3%) cases with sorafenib resistance have high p-MET expression, whereas only one of 17 (5.88%) sorafenib sensitive cases were observed to have positive staining for p-MET (Supplementary Figure S1) .
Anti-proliferative effect of cabozantinib on HCC cells in vitro
The effect of cabozantinib on proliferation in each HCC cell line is shown in Figure 1 inhibitory activity of cabozantinib on VEGFR2 is not involved in its anti-proliferative effects on these HCC cells in vitro.
Next, we investigated the effect of cabozantinib treatment on MET-dependent signaling pathways.
Marked suppression of p-MET was observed in MHCC97L and MHCC97H cells tested after 4 h incubation with cabozantinib at concentrations as low as 10 to 100 nM. Moreover, treatment with these doses also effectively abrogated the phosphorylation of downstream effectors, such as STAT3, AKT, and ERK1/2 ( Figure 3B ). Thus, constitutive activation of these proliferative and survival effectors in MHCC97L and MHCC97H cells appears to depend specifically on MET signaling. In contrast, in SK-HEP1 and HepG2 cells, where MET is not constitutively phosphorylated, cabozantinib at a dose of 100 nM had no demonstrable effect on the phosphorylation of STAT3, AKT, or ERK1/2, indicating that these proliferative and survival effectors are likely activated through alternative growth factor receptors. An increase in the concentration of cabozantinib, up to 5,000 and 10,000 nM, had a significant impact on the phosphorylation of STAT3, AKT, and ERK1/2 in both SK-HEP1 and HepG2 cells ( Figure 3B ). This effect may be because cabozantinib has a non-specific inhibitory effect on these effectors or exerted through the inhibition of other cancer-specific cabozantinib targets, such as AXL, RET, and KIT.
In a cytokine-stimulated tyrosine kinase activity assay, we found that cabozantinib treatment resulted in the marked inhibition of cytokine-stimulated phosphorylation of MET and VEGFR2 and their resultant downstream effectors in HUVECs ( Figure 3C ). In a concentration-dependent manner, cabozantinib eliminated HGF-induced MET phosphorylation and its downstream effectors STAT3, Akt, and Erk-1/2 in both SK-HEP1 and HepG2 cells ( Figure 3D ).
Research. 
Cabozantinib inhibits HGF-induced cell motility and invasion
Because MET is not necessary for proliferation of SK-HEP1 and HepG2 cells, we utilized these two cell lines to test whether cabozantinib has an effect on motility and invasion. We observed that HGF enhanced the migration and invasion of SK-HEP1 and HepG2 cells as evaluated by a wound healing and Transwell assays. Moreover, at a concentration that has minimal impact on growth, cabozantinib inhibited HGF-induced migration and invasion in both SK-HEP1 and HepG2 cells (Figure 4 ). These findings reflect the potential anti-metastatic effect of cabozantinib in HCC cells.
In vivo efficacy and mechanism of cabozantinib against MHCC97H and HepG2 xenografts
To examined that cabozantinib inhibits VEGFR2 and MET signaling activity in vivo, established 
Cabozantinib prevents metastasis of SK-HEP1 cells to the lung and liver
To determine whether cabozantinib treatment could reduce metastasis, SK-HEP1 cells were directly injected into the tail vein of female nude mice. After injection, mice received sorafenib or cabozantinib treatment for four weeks. We found that the formation of metastases in the lung and liver was reduced by 53.7% and 52.9% in cabozantinib-treated group, respectively, compared with the vehicle-treated group (Figure 7) . Interestingly, lungs and livers from mice in the sorafenib-treated group displayed an apparent increase in metastatic foci. Additional evidence of the inhibition of metastasis in cabozantinib-treated group was confirmed by the significant difference in whole lung wet weights among control, sorafenib and cabozantinib treatment groups ( Figure 7A Figure S5) . Cabozantinib treatment was well tolerated, as determined by stable body weights throughout the 28 days treatment period.
Discussion
Targeting angiogenesis has become an established therapeutic approach to fighting solid tumor growth in cancer patients, and the systemic therapy with sorafenib represents a milestone in advanced HCC. However, the benefit of sorafenib in clinical therapy is marginal and transient (8, 9) .
The MET pathway has been found involved in gefitinib resistance in lung cancer (15) . In line with this, we revealed that high level of activated MET in HCC is associated with resistance to adjuvant Recent studies have demonstrated that anti-angiogenesis agents could increase local invasion and distant metastasis during or after treatment (11, 12, 36, 37) . For example, VEGFR inhibitors, such as sorafenib and sunitinib, can result in upregulation of MET, leading to promotion of metastasis (19, 32, 38) . In support of this, we observed that sorafenib treatment promoted metastasis in the lung and liver, and accompany with activation of MET in experimental metastasis models with SK-HEP1 cells.
This finding argues that simultaneously targeting MET and VEGFR2 may circumvent the "metastatic escape pathways". Indeed, mice treated with cabozantinib had fewer metastastic foci in lung and liver tissues compared to control and sorafenib treated groups，suggesting that cabozantinib could reduce tumor metastasis mainly through inactivation of MET. Interestingly, our observations raise the possibility that MET could be activated during tumor progression and sorafenib treatment, leading to enhanced metastasis, thereby identifying a potential target for therapeutic intervention.
In summary, our study revealed that the high level of p-MET in HCC tissue could be a prognosticator of resistance to adjuvant sorafenib therapy. The inhibition of both VEGFR2 and MET signaling pathway by cabozantinib could have considerable therapeutic effects in HCC in vitro and in vivo.
Also, the presence of MET activation in HCC may be a promising biomarker for predicting the response to cabozantinib treatment. Altogether, cabozantinib could be a useful agent for inhibiting tumor growth, angiogenesis, and metastasis in HCC with dysregulated MET and VEGFR2 signaling pathway. Following the experimental design as described in the Materials and Methods, nude mice were sacrificed at day 28 to evaluate lung and liver metastases. The image is a representative hematoxylin and eosin (H&E)-stained section of (A) lung and (B) liver metastases, and the average number of foci is presented as the mean ± SD. * P < 0.05 and **p < 0.01, treated group vs. control group. Scale bars in A and B 40×, 500 μm. Scale bars in A and B 200×, 100 μm.
